Short answer
Prestige Consumer Healthcare Inc. (PBH) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $274M (down 3.4% year over year) with net income of $42M.
Q3 2025 key financials · XBRL
- Revenue
- $274M
- −3.4% YoY · +9.9% QoQ
- Net income
- $42M
- −22.4% YoY · −11.1% QoQ
- Operating margin
- 29.1%
- Gross margin
- 55.3%
- EPS (diluted)
- $0.86
- −20.4% YoY · −9.5% QoQ
Source: XBRL data from the Prestige Consumer Healthcare Inc. (PBH) Q3 2025 10-Q on SEC EDGAR. USD.
Prestige Consumer Healthcare Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $274.1M, down $9.7M or 3.4% YoY
- Gross margin 55.3% vs 55.5% YoY
- Best category Gastrointestinal $46.4M, up 10.7%; worst Eye & Ear Care $29.4M, down 18.7%
- Cash $119.1M, up $21.2M; operating cash flow $136.5M, up $11.9M
- Supply shortages, inflation, tariffs, and trade restrictions threatening demand, costs, and availability
Risk Factors
- Quarterly revenue volatility risk, with results potentially below analyst and investor expectations
- Market valuation risk, with weaker results potentially reducing outstanding-securities prices
- Share-repurchase liquidity risk, with $138.716 million remaining under the $300.0 million authorization
- Insider-trading compliance risk, with an executive’s Rule 10b5-1 plan covering 12,594 shares through September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Prestige Consumer Healthcare Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.